Skip to content

Genome-based Management of Patients in Precision Medicine (Ge-Med) Towards a Genomic Health Program

Genome-based Management of Patients in Precision Medicine (Ge-Med) Towards a Genomic Health Program

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04760522
Acronym
GE-MED
Enrollment
12000
Registered
2021-02-18
Start date
2021-06-01
Completion date
2027-07-31
Last updated
2023-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Predisposition to Disease, Rare Diseases

Keywords

Rare Diseases, Genetic Predisposition, Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), Familial cancer syndromes, Polygenic Risk Scores (PRS)

Brief summary

The GE-MED APPROACH project will enroll patients (n = appr. 12.000) with unclear molecular cause of the disease, suspected genetic cause of the disease without detailed molecular analysis like Whole Exome Sequencing (WES). The novelty of this study is to integrate genomic health concepts into immediate clinical care. To achieve these goals, a novel structure for the Triple P (3P) concept of personalized medicine (Personalized, Predictive, Preventive) integrated into a well-established health care system and associated with novel decentralized Disease Analysing Task Forces (DATF) will be implemented. The overall goal of this study is to implement, for the first time, Whole Genome Sequencing (WGS) analysis as a first line diagnostic test for all clinical indications such as Rare Disease (RD )and familial cancer syndromes.

Interventions

GENETICWGS Diagnostic: Blood take for genetic diagnostic

Blood sampling, short clinical characterization, WGS based sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics).

Sponsors

University Hospital Tuebingen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Unclear molecular cause of the disease * Suspected genetic cause of the disease

Exclusion criteria

* Missing informed consent of the patient and if applicable the legal representative * Previously performed WES or panel analysis

Design outcomes

Primary

MeasureTime frameDescription
Number of WGS analysisDay 1WGS analysis as a first line diagnostic test for all clinical indications

Countries

Germany

Contacts

Primary ContactOlaf Rieß, Prof. Dr.
olaf.riess@med.uni-tuebingen.de+49 7071 29
Backup ContactAndreas Dufke, PD Dr.
andreas.dufke@med.uni-tuebingen.de+49 7071 29

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026